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Evaluation of treatment response
and resistance in metastatic renal
cell cancer (mRCC) using integrated
18F–Fluorodeoxyglucose (18F–FDG) positron
emission tomography/magnetic resonance
imaging (PET/MRI); The REMAP study
Christian Kelly-Morland1* , Sarah Rudman2, Paul Nathan3, Susan Mallett4, Giovanni Montana5, Gary Cook1
and Vicky Goh1
Abstract
Background: Tyrosine kinase inhibitors are the first line standard of care for treatment of metastatic renal cell
carcinoma (RCC). Accurate response assessment in the setting of antiangiogenic therapies remains suboptimal as
standard size-related response criteria do not necessarily accurately reflect clinical benefit, as they may be less
pronounced or occur later in therapy than devascularisation. The challenge for imaging is providing timely
assessment of disease status allowing therapies to be tailored to ensure ongoing clinical benefit. We propose
that combined assessment of morphological, physiological and metabolic imaging parameters using
18F–fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F–FDG PET/MRI)
will better reflect disease behaviour, improving assessment of response/non-response/relapse.
Methods/design: The REMAP study is a single-centre prospective observational study. Eligible patients with
metastatic renal cell carcinoma, planned for systemic therapy, with at least 2 lesions will undergo an integrated
18F–FDG PET and MRI whole body imaging with diffusion weighted and contrast-enhanced multiphasic as well as
standard anatomical MRI sequences at baseline, 12 weeks and 24 weeks of systemic therapy allowing 18F–FDG
standardised uptake value (SUV), apparent diffusion co-efficient (ADC) and normalised signal intensity (SI)
parameters to be obtained. Standard of care contrast-enhanced computed tomography CT scans will be performed
at equivalent time-points. CT response categorisation will be performed using RECIST 1.1 and alternative (modified)
Choi and MASS criteria. The reference standard for disease status will be by consensus panel taking into account
clinical, biochemical and conventional imaging parameters. Intra- and inter-tumoural heterogeneity in vascular,
diffusion and metabolic response/non-response will be assessed by image texture analysis. Imaging will also inform
the development of computational methods for automated disease status categorisation.
(Continued on next page)
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Discussion: The REMAP study will demonstrate the ability of integrated 18F–FDG PET-MRI to provide a more
personalised approach to therapy. We suggest that 18F–FDG PET/MRI will provide superior sensitivity and specificity
in early response/non-response categorisation when compared to standard CT (using RECIST 1.1 and alternative
(modified)Choi or MASS criteria) thus facilitating more timely and better informed treatment decisions.
Trial registration: The trial is approved by the Southeast London Research Ethics Committee reference 16/LO/1499
and registered on the NIHR clinical research network portfolio ISRCTN12114913.
Keywords: Metastatic renal cell carcinoma, Magnetic resonance imaging, Positron emission tomography, Pet/MRI,
Response assessment
Background
Renal cell carcinoma (RCC) is currently the ninth com-
monest cancer with a worldwide incidence of 2.4% in
2012 [1]. Usually presenting in the sixth and seventh
decades of life, and commoner in men than women, the
incidence of the disease has been rising steadily at
approximately 1.1% per year over the last decade [2].
The commonest histological subtype of RCC is clear cell,
accounting for 70% of cases with papillary RCC and the
more indolent chromophobe subtype contributing to the
remaining majority. Rarer entities such as the aggressive
collecting duct carcinoma account for less than 5% of
cases [3]. The five-year survival rate in metastatic RCC
remains poor at less than 12% [4]. Metastatic disease is
present in up to 30% of patients at the time of diagnosis
with up to a further 30% of patients subsequently devel-
oping metastases in the ensuing two years despite resec-
tion of the primary tumour [5].
Treatment options
Systemic treatment options for metastatic RCC have
shifted to targeted therapies in the last decade following
demonstration of improved progression free survival in
Phase III clinical trials [6–12]. Renal cell carcinoma can
be a highly vascular tumour, for example, related to
Von-Hippel Lindau gene mutations and accumulation of
hypoxia inducible factor (HIF). Transcriptional targets of
HIF include vascular endothelial growth factor (VEGF)
and platelet derived growth factor (PDGF), with upregu-
lation of angiogenesis, hence why anti-angiogenic tar-
geted therapies have been successful in metastatic RCC.
A number of targeted agents have received FDA
approval for metastatic RCC. These include the small
molecule multi-kinase inhibitors including pazopinib,
sunitinib, sorafenib and axitinib, the mammalian target
of rapamycin (mTOR) inhibitors everolimus and temsir-
olimus, and the monoclonal antibody Bevacizumab, an
inhibitor of vascular endothelial growth factor A. These
agents selectively inhibit neo-angiogenesis and cell pro-
liferation respectively through a variety of signalling
pathways [13] including the RAS-RAF-MEK-ERK and
PI3K-AKT-mTOR pathways (Fig. 1). These agents have
been shown to positively impact survival with transient
stabilisation of disease in 70% of patients as well as pro-
viding scope for several lines of treatment [6–12]. More
recently clinical trials of immunotherapeutic agents have
also shown promise. These agents stimulate the immune
system to destroy cancer cells and the possibility of a
synergistic effect between immunotherapy and targeted
therapy is under investigation [4]. The CheckMate 025
phase III multicentre trial of 821 patients demonstrated
that the programmed (T-cell) death-1 (PD-1) inhibitor,
nivolumab, which potentiates the native T-cell response
has demonstrated favourable an overall survival benefit
with a 27% reduction in the risk of death as well as a
greater response rate (25% versus 5%) when compared
to treatment with everolimus [14].
Fig. 1 Illustrating the sites of action of the targeted chemotherapies
in renal cell carcinoma. The cell proliferation and angiogenisis
cell-signalling pathways are up-regulated in malignancy and can be
targeted at the level of the receptors (Pazopinib, Sunitinib), agonist
(Bevacizumab) or downstream signalling pathways (Temsirolimus,
Everolimus). VEGF: Vascular endothelial growth factor, PDGF: Platelet
derived growth factor, mTOR: mammalian target of rapamycin, PI3K:
phosphatidylinositol 3-kinase, AKT: protein kinase B, ERK: Extracellular
signal-regulated kinase
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The need for alternative imaging response biomarkers
Our preliminary work in patients treated with multi-
kinase inhibitors has shown that different clinical imaging
patterns may be observed with treatment [15]. New
metastases may appear even if pre-existing lesions remain
stable. Changes in size and/or vascularisation of existing
lesions may occur either rapidly or slowly. Proposed vas-
cular mechanisms of resistance include: 1) Up-regulation
of alternative pro-angiogenic pathways, allowing the
development of new abnormal tumour vessels, restoring
tumour angiogenesis to its pre-treatment level and allow-
ing rapid tumour growth; 2) Development of alternative
metabolic pathways independent of vascular supply, which
may represent a more aggressive phenotype; 3) Recruit-
ment of vascular progenitor cells, pro-angiogenic mono-
cytes, pericytes, or co-option of normal vessels, thus
reconstituting vessels which do not have the typical char-
acteristics of tumour vessels. These pseudo-normal vessels
are inefficient resulting in a slower tumour re-growth rate.
Assessing response to targeted therapies with the
internationally accepted response evaluation criteria in
solid tumours version 1.1 (RECIST 1.1) has been chal-
lenging in this setting. With RECIST 1.1 percentage
changes in the sum of maximal unidirectional measure-
ments of target visceral or short axis nodal metastatic
lesions over time are used to categorise treatment
response, disease stability or progression [16]. However
targeted therapies do not necessarily lead to a concomi-
tant size reduction [15, 17]. Indeed immunotherapies
such as ipilimumab and pembrolizumab may also ini-
tially increase lesion size, in up to 15% of cases during
successful therapy (‘pseudoprogression’) [18]. This may
be due to the accumulation of inflammatory infiltrates
secondary to the augmented immune response [19]. One
such study of Pembrolizumab in 411 patients treated for
metastatic melanoma found that 12% of patients demon-
strated an initial increase in metastatic lesions that
would have led to a classification of progressive disease
by RECIST 1.1 despite a decline in overall tumour bur-
den over time [20, 21]. In order to prevent premature
cessation of efficacious treatment and conversely contin-
ued treatment with ineffective treatment there is a need
to improve imaging response assessment. An example of
preliminary work is the incorporation of changes in
tumour density (Hounsfield unit attenuation) measured
on contrast enhanced computed tomography (CT) with
size change [22, 23] and immune response criteria [20].
We propose that in vivo imaging targeted at the mode
of drug action, its downstream effects, and a better
understanding of the mechanisms underlying tumour
response and resistance will enable imaging to provide a
better indication of therapeutic effect. Hybrid positron
emission tomography/magnetic resonance imaging (PET/
MRI) scanners enables PET tracers such as the glucose
analogue fluorine 18 (18F) fluorodeoxyglucose (FDG) to be
combined with multi-parametric MRI including multi-
phasic contrast enhanced and diffusion weighted
sequences. Preliminary studies of 18F–FDG PET alone
[24–30] or MRI alone [31–34] have suggested a role
for these modalities as response biomarkers. 18F–FDG
PET has a high sensitivity and specificity for extra-
renal lesions with a sensitivity and specificity of up to
84% and 91% in detecting metastases, which appear
hypermetabolic and and a Phase II study of 44 pa-
tients has shown that reduction in the FDG metabolic
activity and tumour size is associated with overall and
progression free survival [24]. A high baseline FDG
standardised uptake value (SUV) also correlates with
disease aggressiveness [26, 35, 36].
The REMAP study will examine whether the perform-
ance of integrated FDG-PET/MRI is better than standard
of care imaging for response categorisation in metastatic
RCC patients undergoing targeted therapy. We hypothe-
sise that integrated 18F–FDG PET/MRI combining ana-
tomic, metabolic and physiological imaging will be able to
detect response/resistance ahead of size change allowing
non-responding patients to transition to alternative ther-
apies more swiftly. An integrated whole body technique
will also allow for the heterogeneity of response to be
explored within and between lesions, building on existing
work [37]. PET/MRI will also facilitate the assessment of
potential effects of therapy e.g. angiogenesis inhibition or
immune modulation on normal organ microvasculature,
which underlie treatment co-morbidities, e.g. hyperten-
sion as suggested in our previous work [38].
Methods/design
Study design
The REMAP study is an investigator initiated single
centre observational study. All participants will have to
provide written informed consent, signed and dated
before inclusion in the study. The study is registered on
the NIHR CRN portfolio ISRCTN12114913.
Study organisation
The sponsor is King’s College London and Guy’s & St
Thomas’ Hospitals NHS Trust, London. The study is
funded by Cancer Research UK (CRUK award reference
C42827/A20000) and will be carried out at the King’s
College London and Guy’s and St Thomas’ PET Centre,
London.
Ethical approval
The final protocol has been approved by the Southeast
London Research Ethics Committee (ref: 16/LO/1499)
and approved by the Administration of Radioactive
Substances Advisory Committee of the Dapratment of
Health (ARSAC), UK.
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Study population
Thirty eight patients with proven metastatic renal cell
carcinoma will be recruited into the study. Patient inclu-
sion and exclusion criteria are summarised in Table 1. A
staging CT is required. Study entry will be restricted to
patients in whom there is at least one lesion 2 cm or
greater in size in order to minimise partial volume
effects in 18F–FDG PET/MRI.
Study objectives & endpoints
The primary objective of the REMAP study is to
compare integrated 18F–FDG PET/MRI with CT for
response categorisation at 12 weeks and 24 weeks on
treatment and to assess the sensitivity and specificity
of integrated 18F–FDG PET/MRI metrics to predict
for disease progression after 12 and 24 weeks on
treatment (PET: FDG standardised uptake value
(SULpeak); MRI: diffusion MRI apparent diffusion co-
efficient (ADC) and post-gadolinium contrast agent
normalised tumour signal intensity (SInorm), (alone or
in combination).
Secondary objectives are; 1) to compare 18F–FDG
PET/MRI response categorisation versus RECIST 1.1
and exploratory combined size & enhancement criteria
(e.g. Choi, modified Choi and MASS [39–41]; 2) to as-
sess if whole body tumour burden is better than target
lesions only for response categorisation (RECIST 1.1); 3)
to assess and quantify the inter-lesional heterogeneity in
responding/non-responding lesions by texture analysis
and 4) to explore whether there is a consistent effect of
therapy on normal organ physiology e.g. kidney, liver,
spleen.
The primary endpoint is the number of responders/
non-responders on 18F–FDG PET/MRI versus standard
CT at 12 and 24 weeks and a consensus reference stand-
ard based on all patient information up to 36 weeks.
Time to progression and progression free survival
beyond 36 weeks will also be recorded in order to
determine if 18F–FDG PET/MRI metrics can predict for
disease progression.
Imaging
Computed tomography (CT)
Contrast enhanced CT of the thorax, abdomen and
pelvis (100-120kVp, dose modulated mA, matrix
512 × 512, field of view 35 cm, ≤5 mm reconstructed
slice thickness, following intravenous administration of
100 ml of ≥300 mg/ml iodinated contrast agent at 3 mL/s)
will be performed as part of the patient’s standard clinical
care at baseline and 12, 24 and 36 weeks ±21 days post-
commencement of systemic therapy.
18F FDG-pet/MRI
Up to 400 MBq of 18F–FDG will be administered intraven-
ously. Following a 60 ± 5 min uptake period simultaneous
18F–FDG PET/MRI will be undertaken. 18F–FDG PET
with a 2-point Dixon based segmentation technique uti-
lised for attenuation correction, T1-weighted, T2-weighted,
diffusion weighted (b-values: 50, 900 s/mm2) and multi-
phasic post contrast T1-weighted sequences (arterial,
portal venous and equilibrium) following intravenous ad-
ministration of gadolinium (0.1 mmol/kg) will be obtained
from vertex to mid-thigh. 18F–FDG PET/MRI will be
performed within 2 weeks of the standard CT scans. Each
18F–FDG PET/MRI will incur a maximal estimated radi-
ation dose of 7.3mSV compared to a maximal estimated
19mSV per CT of the thorax, abdomen and pelvis.
Categorisation of response
RECIST 1.1
Categorisation of response, disease stability or disease
progression will be by RECIST 1.1 at 12, 24 and 36 weeks
for target and non-target lesions. This is summarised in
Table 2. This will be performed for each CT.
Size & enhancement criteria
Categorisation of response, disease stability or disease
progression will be by Choi, modified Choi (mCHOI)
and MASS criteria at 12, 24 and 36 weeks for target and
non-target lesions. This is summarised in Table 2. This
will be performed for each CT.
18F FDG-PET/MRI metrics
Categorisation of response, disease stability or disease
progression using 18F–FDG PET/MRI metrics are sum-
marised in Table 3. For 18F–FDG PET alone this is as
per PERCIST [42]. A measurable target lesion is defined
as the single tumour lesion with highest uptake value.
SULpeak (maximal 1.2-cm diameter volume ROI in
tumour) has to be at least 1.5-fold greater than liver
SULmean in a 3-cm diameter ROI in normal right lobe of
liver (or 2-fold greater than the SULmean of blood pool
in 1-cm-diameter ROI in the descending thoracic aorta
extended over 2-cm z-axis if the liver is abnormal).
Table 1 Patient recruitment
Inclusion criteria
1. Adults (>18 years) capable of providing informed consent with
metastatic renal cell cancer
2. Eastern cooperative oncology group (ECOG) performance
status ≤ 2
Exclusion criteria
1. Estimated prognosis < 12 weeks
2. Contraindications to contrast enhanced CT, MRI or FDG/PET
3. Women who are pregnant or lactating
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Reference standard for response categorisation:
Disease status (PD/non-PD, per patient and per lesion)
by consensus will be confirmed using clinical criteria
and all conventional imaging up to 36 weeks on treat-
ment. The time-point of PD up to 36 weeks defined by
consensus will be recorded. This time point is based on
previous data (Median TTP: 336 days [37]).
Additionally computational methods for predicting
response/non-response will be developed using two
complementary approaches: a) state-of-the-art ma-
chine learning models, e.g. boosting and support vec-
tor machines based on customised kernel functions;
b) novel “deep” neural networks architectures that are
capable of automatically extracting predictive features
in a completely data-driven manner.
Sample size and analysis
This is a feasibility study with the sample size (n = 38)
based on estimating parameters needed to design a fu-
ture efficacy study. Parameters estimated from this feasi-
bility study will be (i) the sensitivity and specificity of
18F–FDG PET/MRI (new test) to detect progressive dis-
ease after 12 & 24 weeks on treatment; (ii) the difference
in sensitivity and correlation of 18F–FDG PET/MRI
compared to CT RECIST (standard test). Additional
assumptions tested will be the prevalence of disease
progression and the best timepoint for detection of
disease progression. The sample size of 38 patients, 19
with disease progression, will allow for an estimation of
sensitivity of 18F–FDG PET/MRI with a 95% confidence
intervals lower limit precision of within 20%. The
Table 2 Response assessment criteria
RECIST CHOI mCHOI MASS
Progressive disease
(MASS unfavourable response)
Increase in sum of
longest target lesion
diameters >20%.
or
Development of new
lesions.
or
Unequivocal non-target
lesion progression.
Increase in lesion
sizea > 10%.
or
Development of new lesions.
or
New or enlarging
intratumoral nodule.
Increase in lesion
sizea > 10%.
or
Development of new lesions.
or
New or enlarging
intratumoral nodule.
Increase in lesion
sizea > 20% without
central necrosis.
or
Development of new
lesions.
or
New intratumoral
enhancing components.
Partial response
(MASS favourable response)
>30% decrease in sum of
longest target lesion
diameters.
Decrease in target lesion CT
enhancement (Hounsfield
units) >15% or size >10%
Decrease in target lesion CT
enhancement (Hounsfield
units) >15% and size >10%
Decrease in lesion size
>20%, central necrosis or
reduction in attenuation
>40 Hounsfield units
Complete response Disappearance of all
target lesions and
resolution of
lymphadenopathy
(<10 mm).
Disappearance of all target
lesions
Disappearance of all target
lesions
Disappearance of all
target lesions
Stable disease (MASS
indeterminate response)
None of the above None of the above None of the above None of the above
aLesion size refers to the sum of the longest diameter of up to 10 target lesions (two per organ)
Table 3 PET/MRI response categorisation
Category/Parameter Complete Response (CR) Partial Response (PR) Stable Disease (SD) Progressive Disease (PD)
18F FDG PET SULpeak Resolution of target
lesion activity: activity less
than mean liver activity &
indistinguishable from
background blood-pool
levels. Disappearance of
all other lesions to back-
ground blood-pool levels.
≥30% reduction of target
lesion SULpeak. Absolute
decrease ≥0.8 SUL units.
Measurement is
commonly in same lesion
as baseline but can be
another lesion if this is
now the most active
lesion after treatment.
Does not fulfil criteria for
response or progression
>30% increase of target
lesion SULpeak. New
18F FDG avid lesions.
DW-MRI
ADC50–900
Resolution of DWI signal Persistence of DWI signal;
>30% increase in
ADCmean
Does not fulfil criteria for
response or progression
Persistence of DWI signal;
>25% reduction in
ADCmean
DCE-MRI
SInormalised
Resolution of
enhancement
Persistence of
enhancement; >40%
decrease in SInorm
Does not fulfil criteria for
response or progression
Persistence of
enhancement; >40%
increase in SInorm
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expectation is that 95% of patients from the same clinical
population will have a sensitivity within these 95% confi-
dence intervals (CI). The assumptions for this feasibility
study are a prevalence of patients with PD of 50%; 18F–
FDG PET/MRI 80% sensitivity per patient for PD; and 10%
loss to follow up. Sensitivity and specificity per patient will
be compared using paired comparison of proportions of (i)
18F–FDG PET/MRI & (ii) CT RECIST to detect PD.
Discussion
Accurate and timely response assessment in metastatic
RCC is important to facilitate changes in treatment, in
particular discontinuing non-efficacious, costly treatment
that may be associated with toxicity. It is well known that
conventional response assessment based on size does not
best reflect the clinical effectiveness of cytostatic targeted
therapies as size changes lag behind actual response and
relapse in the majority of cases [15]. Assessment of the
downstream effects of therapy on tumour vascularisation,
glucose metabolism and water diffusion with integrated
hybrid imaging potentially provides a more personalised
approach to therapeutic evaluation.
It is well known that tumour vascularisation is heteroge-
neous. During growth tumours either co-opt a vascular
supply from adjacent normal vessels, incite new vessel
growth de novo (vasculogenesis), or from existing vascula-
ture (angiogenesis) [43, 44]. The resultant tumour vessel
architecture is disorganised and dysfunctional. Areas of
adequate or hyperperfusion may co-exist with areas of
hypoperfusion or high permeability (leading to increased
intra-lesional interstitial fluid pressure and hypoxia).
This variation in haemodynamic status will influence
therapy delivery and its effectiveness [43]. Assessment
of CT Hounsfield units (enhancement characteristics)
in addition to size has already been performed to
augment response assessment [15]. Several varying
response patterns have been described in the litera-
ture ranging from a correlative reduction in tumour
CT density (enhancement) and size to a reduction in
tumour CT density with stabilisation of disease, or
conversely minimal change in tumour CT density
with at best disease stabilisation or progression [15].
There is little specific data of FDG PET for response
assessment in metastatic RCC [45] but small studies
(10–30 patients) have found that FDG PET metabolic
response may occur within 1 cycle of therapy [46] and
possibly as early as 2 weeks into treatment [47] with
sunitinib or sorafenib as first or second line therapy.
There is also evidence of a strong correlation between
the number and 18F–FDG avidity of lesions and overall
survival in patients on targeted therapy [24]. One study
examined 243 metastatic lesions in 26 patients and dem-
onstrated a significantly worse median survival time
amongst patients in whom the maximum SUV of the
primary tumour was >8.8 [48]. A subsequent larger
study involving 60 patients also showed a higher mortal-
ity of 62.5% in those patients in whom the maximum
SUV of the primary was >10 versus 33.3% in cases where
the maximum SUV measured 3–5.
Diffusion weighted MRI may also provide relevant
biological information. Investigators have demonstrated
that a positive correlation exists between primary
tumour grade and ADC values in a group of 33 patients;
there was a statistically significant downward trend in
the ADC value of lesions as grade increased [49]. A
further study of 47 patients with metastatic renal cell
carcinoma did not find baseline whole tumour mean
ADC to be a predictor of outcome prior to the com-
mencement of targeted therapy but there was a positive
correlation between overall survival and the proportion
of tissue within the tumour below the 25th percentile
point of the cumulative ADC histogram [33]. It has also
been shown that diffusion weighted imaging and multi-
phasic contrast enhanced MRI signal intensity may alter
in response to treatment in renal cell cancer [33].
There are few data correlating imaging with mecha-
nisms of relapse. A number of potential mechanisms
underlying varying responses have been proposed with
preclinical studies demonstrating an up-regulation of the
production of the pro-angiogenic cytokine IL-8 associ-
ated with the development of sunitinib resistance, the
same study found that the tumours in murine models
were subsequently re-sensitised to sunitinib following
the administration of an IL-8 neutralising antibody and
began to respond to therapy despite previous failure
[50]. Another potential factor in the development of
drug resistance is the upregulation of hypoxia inducible
factor 1-alpha (HIF-1a) in response to the hypoxic
microenvironment induced by anti-angiogenic therapy.
The presence of HIF-1a can lead to upregulation of ex-
pression of the RTK MET genes leading to potentiation
of the MAPK tumorigenesis pathways [51].
It is clear that further research is needed to add to the
body of evidence supporting alternative imaging bio-
markers of treatment response/non-response/relapse in
this arena for which PET/MRI is ideally suited. Simultan-
eous acquisition of data relating to tumour metabolic ac-
tivity, perfusion and diffusion in a single, streamlined,
integrative examination will provide a more representative
and comprehensive picture of underlying biological mech-
anisms of therapy. Data from this pilot study will also
provide the necessary initial evidence to power a future
multicentre study. This study will also explore the quanti-
tation of heterogeneity of therapy response both within
and between metastases and provide preliminary data for
computational methods that are capable of automatically
extracting predictive features in a completely data-driven
manner.
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Conclusion
In conclusion, the REMAP study will provide initial
evidence for the sensitivity and specificity of 18F–FDG
PET/MRI to detect disease response/non-response in
metastatic renal cell cancer treated with targeted therap-
ies, and how its performance in response categorisation
compares to standard CT RECIST 1.1.
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